Hypertension control during the COVID-19 pandemic: results of the MMM2021 in Russia

O. P. Rotar,A. M. Erina, M. A. Boiarinova, E. V. Moguchaia, E. P. Kolesova, K. M. Tolkunova, A. R. Gorshevaya, K. A. Kovalenko,E. A. Smirnova, Ya. A. Belenikina, I. V. Bikushova, M. A. Kercheva, A. V. Svarovskaya,M. M. Petrova, D. S. Kaskaeva, P. A. Shcherbina,S. Yu. Nikulina,A. A. Chernova, A. V. Levshin, A. O. Shabelsky, E. I. Zheleznyak, E. A. Kartashova, Yu. A. Sharapova,T. M. Chernykh, M. V. Derevyanchenko, V. V. Fedotov,N. Yu. Shaposhnikova, E. R. Makeeva, O. V. Ulitina,M. V. Menzorov, E. M. Dolya, A. A. Tanicheva,A. O. Konradi, E. V. Shlyakhto

Russian Journal of Cardiology(2022)

引用 2|浏览2
暂无评分
摘要
Repetitive quarantines and social restrictions during the coronavirus disease 2019 (COVID-19) pandemic have negatively affected the population health in general, and the control of hypertension (HTN) in particular.Aim. To evaluate the control of HTN in the Russian population during the COVID-19 period based on the results of screening for HTN May Measurement Month 2021 (MMM2021).Material and methods. During May-August 2021, 2491 participants from 11 Russian regions took part in the screening. Participation was voluntary without restrictions on sex. All participants were over 18 years of age. During the screening, blood pressure (BP) was measured three times using automatic and mechanical BP monitors. In addition, a questionnaire was filled out on behavioral risk factors, comorbidities and therapy. HTN was diagnosed with systolic BP ≥140 mmHg and/ or diastolic blood pressure ≥90 mmHg and/or taking antihypertensive therapy. The questionnaire included questions about prior COVID-19, vaccinations and their impact on the intake of antihypertensive drugs.Results. The analysis included data from 2461 respondents aged 18 to 92, of which 963 were men (39,1%). The proportion of hypertensive patients was 41,0%, while among them 59,0% took antihypertensives and 30,9% were effectively treated. In comparison with pre-pandemic period according to MMM2018-2019, the higher proportion of HTN patients in the Russian sample was revealed during MMM2021 (41,0% vs 31,3%, p<0,001) with a comparable proportion of patients receiving antihypertensive therapy (60,7% vs 59,0%, p=0,05) and treatment efficacy (28,7% vs 30,9%, p=0,36). Monotherapy was received in 44,7% of cases, while dual and triple combination therapy — in 30,9% and 14,1%, respectively. The majority of respondents (~90%) did not adjust their antihypertensive therapy during the COVID-19 pandemic.Conclusion. According to HTN screening in Russia, there is persistent ineffective control of HTN, which may be due to both the worsening pattern of behavioral risk factors, limited access to healthcare during COVID-19, and the inertia of physicians and low adherence of patients due to the asymptomatic HTN course in the majority.
更多
查看译文
关键词
screening,hypertension,blood pressure,adherence,covid-19
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要